Denmark · Delayed Price · Currency is DKK Demant Earnings Call Transcripts
Fiscal Year 2025
-
Reported 2% organic growth for 2025, with strong Q4 performance in Hearing Care and Diagnostics, but margin pressure from ASP and mix. 2026 guidance targets 3%-6% organic growth, DKK 4.1-4.5bn EBIT, and cost savings, with Zeal rollout and KIND acquisition as key drivers.
-
Q3 results landed at the low end of expectations, with 3% organic growth and margin pressure from negative ASP and mix effects. Market share gains were achieved in hearing aids, and the Oticon Seal launch drew strong interest. 2025 guidance remains, but at the lower end of the range.
-
Flat organic growth and margin contraction in H1 2025 were driven by weak market conditions, unfavorable mix, and FX headwinds. EBIT guidance and market growth expectations were revised down, while strong cash flow and the KIND Group acquisition marked key developments.
-
The acquisition of Kind Group for EUR 700 million expands the company's presence in Germany, creating one of the largest retail footprints in the market. Synergies are expected to drive profitability, with full benefits realized by 2028, and the deal is projected to be earnings accretive from year one.
-
A €700 million acquisition of a leading German hearing care retailer will expand the buyer's global clinic network, strengthen its market position, and is expected to add €300 million in revenue by 2026. Integration will be gradual, with no immediate layoffs planned.
-
Q1 2025 saw flat organic growth and a decline in hearing aid sales due to U.S. market weakness and currency headwinds, prompting a downward revision of full-year guidance. Hearing care outperformed the market, while diagnostics remained flat. EBIT guidance was lowered by DKK 400 million.
Fiscal Year 2024
-
Revenue grew 4% in 2024, driven by hearing care and acquisitions, while EBIT declined 2% due to FX and lower leverage. 2025 guidance targets 3%-7% organic growth and DKK 4.5-4.9 billion EBIT, with continued focus on core hearing healthcare and strong cash flow.
-
Q3 delivered strong hearing care growth and stable gross margin, but hearing aids and diagnostics faced headwinds from competition and weak markets, especially in China. Full-year guidance is unchanged, with management expecting a stronger Q4 and continued focus on cost control.
-
Organic growth and EBIT fell short of expectations due to U.S. managed care losses and subdued diagnostics, but strong gross margin and cash flow were supported by higher ASP and product mix. EPOS restructuring and divestments are underway, with a revised outlook for modest growth and profitability.